GI Dynamics, Inc. – ASX Announcement
GI Dynamics, Inc. Announces Interim Data Demonstrating
Clinical Benefits of
EndoBarrier® Treatment in Low BMI Type 2
Diabetes Patients
Data Discussed at 2012 Society of American Gastrointestinal
and Endoscopic Surgeons
(SAGES) Postgraduate Course
Lexington, Massachusetts, United States and Sydney,
Australia – (8 March 2012)
– GI Dynamics, Inc.
(ASX: GID) today announced interim data
from a study that demonstrates glycemic control, weight loss
and other metabolic benefits of the
EndoBarrier® Gastrointestinal Liner
(the EndoBarrier) in type 2 diabetes
patients with low body mass index (BMI). These data were
discussed at the Society of American Gastrointestinal
and
Endoscopic Surgeons (SAGES) 2012 Annual Meeting in San Diego,
Calif., in the pre- meeting, postgraduate course, “Metabolic
Surgery and Cure of Diabetes.”
The study is a non-randomized, single-arm, single-center
study evaluating EndoBarrier treatment in 20 patients with
type 2 diabetes over a one-year period and with one year of
follow-up analysis. The interim analysis comprises treatment
results from the first 10 patients completing the study.
These patients had a mean BMI of 29.8 kg/m2
(ranging from
23-36). Results showed that EndoBarrier treatment reduced
HbA1c levels from 8.8
